Paroxysmal Nocturnal Hemoglobinuria Treatment Market

The global Paroxysmal Nocturnal Hemoglobinuria treatment market size was valued at USD 2.9 billion in 2020 and is anticipated to expand at a CAGR of 11.1% during the forecast period, 2021-2028.. The growth of the market is attributed to the rising adoption of new therapeutics, increasing geriatric population and novel emergence of diagnosis and biologics towards Paroxysmal Nocturnal Hemoglobinuria.
 

Paroxysmal Nocturnal Hemoglobinuria is considered one of the rarest blood diseases which causes the red blood cells present in the host to break apart from each other. This process of breaking the blood cells without reliable recovery is called hemolysis and is considered lethal which can damage the immune systems of the host. The most successful Paroxysmal Nocturnal Hemoglobinuria treatment is in the usage of a drug eculizumab called the Soliris, which binds all the protein to the blood of the host to prevent the breaking of the blood cells.

According to the Centers for Disease Control and Prevention (CDC), in 2019, over 20,000 people were affected by the Paroxysmal Nocturnal Hemoglobinuria and 10,000 of these cases was from North America and Europe. This report also stated that this disease is actually spreading at an exponential rate of 1.3 million people per every subsequent year. The COVID-19 pandemic has hindered the growth of global Paroxysmal Nocturnal Hemoglobinuria treatment market initially. However, scientists & researchers, upon further research, reported & identified that the coronavirus has numerous viral genes that can accelerate the present illness of the hosts. This leads to the rapid arrangement of clinics, healthcare laboratories, and hospitals to expand Paroxysmal Nocturnal Hemoglobinuria treatment and diagnosis for the prevention of this disease. This has led to its market growth in the later stages of the pandemic.

Market Trends, Drivers, Restraints, and Opportunities

• Increase in spending and investing by key companies towards the development of new and advanced Paroxysmal Nocturnal Hemoglobinuria treatment methods is a primary reason to boost the market growth during the forecast period.
• Rapid growth of the biopharmaceutical companies and thereby that industry can become a major factor in the boosting of the global Paroxysmal Nocturnal Hemoglobinuria treatment market during the forecast period.
• High prices for the development of Paroxysmal Nocturnal Hemoglobinuria Treatment diagnosis equipment and high cost of services from the company’s perspective is anticipated to hinder the global market growth.
• Paroxysmal Nocturnal Hemoglobinuria treatment is a relatively new field of venture which has not met the technological requirements to be treated in large scales. This treatment also has adverse side-effects depending upon the patient. This can hamper the Paroxysmal Nocturnal Hemoglobinuria treatment market growth.
• R&D investment and technological advancement are expected to offer significant opportunities for the market players. As of now, there are 16 products and drugs in various stages in terms of clinical development which can be used for the treatment of Paroxysmal Nocturnal Hemoglobinuria. There are also other therapies and treatment methods the medical team is pursuing for the prevention of this diseases including vaccinations and surgeries.

Scope of the Report

The report on the global Paroxysmal Nocturnal Hemoglobinuria Treatment market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Segment Insights

Stem Cell Transplant segment is projected to represent a large market share
Based on treatments, the global Paroxysmal Nocturnal Hemoglobinuria treatment market is divided into medication, stem cell transplant, and blood transfusion. The stem cell transplant segment constituted a major market share in 2019. The major reason for the segment growth is the presence of the only reliable drug used for this treatment called the Soliris. This is used in the stem cell transplant where this drug is injected directly to the patient’s blood stream.

Meanwhile the medication segment is anticipated to expand at a significant CAGR during the forecast period, 2021-2028. This is attributed to the latest technological developments of the pharmaceutical companies to create new drugs which has similar properties of Soliris and can be injected with minimal risks to the patient.
 

 North America is anticipated to dominate the market
On the basis of regions, the global Paroxysmal Nocturnal Hemoglobinuria Treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to dominate the global market with a 35% market share in the coming years owing to the growing research & development expenditure along with the rising in adoption of the latest technology in the region. The demand of Paroxysmal Nocturnal Hemoglobinuria treatment is increasing rapidly in this region due to the presence of the major market players in the Paroxysmal Nocturnal Hemoglobinuria treatment market. The cost of expenditure is significantly lower in North America than that of other economies. However, the market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period as they have prioritized the cost-efficiency perspective of Paroxysmal Nocturnal Hemoglobinuria treatment combined with their growing population.
 

Segments

Segments Covered in the Report
The global Paroxysmal Nocturnal Hemoglobinuria treatment market size has been segmented in terms of

Treatments

• Medication
• Stem Cell Transplant
• Blood Transfusion

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Alexion Pharmaceuticals Inc.
• Akari Therapeutics Plc
• Apellis Pharmaceuticals Inc.
• Amgen Inc.
• CinnaGen Co.
• Ra Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.

Competitive Landscape

Major players competing in the global Paroxysmal Nocturnal Hemoglobinuria treatment market are Alexion Pharmaceuticals Inc.; Akari Therapeutics Plc; Apellis Pharmaceuticals Inc.; Amgen Inc.; CinnaGen Co.; Ra Pharmaceuticals Inc.; and Alnylam Pharmaceuticals Inc. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Alexion Pharmaceuticals Inc. currently is the market leader with its most valuable drug called the Soliris, being the only most efficient drug used for the treatment of Paroxysmal Nocturnal Hemoglobinuria. However, other biopharmaceutical companies have reached final stages of creating their own drugs have similar properties of Soliris, while having lower side-effects with better cost efficiency.